PeptiDream Inc. (4587.T)
JPY 1815.0
(0.83%)
JPY 1815.0
(0.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.03 Billion JPY | -59.81% |
| 2022 | 7.55 Billion JPY | 109.47% |
| 2021 | 3.6 Billion JPY | -18.93% |
| 2020 | 4.44 Billion JPY | 555.34% |
| 2019 | -976.92 Million JPY | -135.27% |
| 2018 | 2.77 Billion JPY | 18.62% |
| 2017 | 2.33 Billion JPY | 23.51% |
| 2016 | 1.89 Billion JPY | 19.57% |
| 2015 | 1.58 Billion JPY | 57.47% |
| 2014 | 1 Billion JPY | 576.15% |
| 2013 | 148.51 Million JPY | 8.26% |
| 2012 | 137.18 Million JPY | 1275.79% |
| 2011 | 9.97 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 18.76 Billion JPY | 2327.52% |
| 2024 Q1 | -842.54 Million JPY | -66.64% |
| 2023 Q1 | -248.8 Million JPY | -103.21% |
| 2023 Q2 | -480.21 Million JPY | -93.01% |
| 2023 Q3 | 4.27 Billion JPY | 989.28% |
| 2023 Q4 | -505.6 Million JPY | -111.84% |
| 2023 FY | 3.03 Billion JPY | -59.81% |
| 2022 FY | 7.55 Billion JPY | 109.47% |
| 2022 Q4 | 7.74 Billion JPY | 718.59% |
| 2022 Q2 | 213.46 Million JPY | 125.74% |
| 2022 Q1 | -829.29 Million JPY | -440.71% |
| 2022 Q3 | 945.64 Million JPY | 342.99% |
| 2021 Q4 | 243.4 Million JPY | -90.2% |
| 2021 FY | 3.6 Billion JPY | -18.93% |
| 2021 Q2 | -226.78 Million JPY | -151.95% |
| 2021 Q3 | 2.48 Billion JPY | 1195.38% |
| 2021 Q1 | 436.51 Million JPY | -88.35% |
| 2020 Q1 | -340.7 Million JPY | 0.0% |
| 2020 FY | 4.44 Billion JPY | 555.34% |
| 2020 Q4 | 3.74 Billion JPY | 2080.4% |
| 2020 Q3 | -189.21 Million JPY | -115.37% |
| 2020 Q2 | 1.23 Billion JPY | 461.33% |
| 2019 Q1 | 86.6 Million JPY | -84.94% |
| 2019 Q2 | 2.07 Billion JPY | 2296.35% |
| 2019 FY | -976.92 Million JPY | -135.27% |
| 2019 Q3 | -185.26 Million JPY | -108.93% |
| 2018 Q2 | 3.16 Billion JPY | 1166.3% |
| 2018 Q3 | 33.3 Million JPY | -98.95% |
| 2018 Q1 | -296.97 Million JPY | -357.42% |
| 2018 Q4 | 575 Million JPY | 1626.73% |
| 2018 FY | 2.77 Billion JPY | 18.62% |
| 2017 FY | 2.33 Billion JPY | 23.51% |
| 2017 Q4 | 115.36 Million JPY | 117.75% |
| 2017 Q3 | -649.77 Million JPY | -137.64% |
| 2017 Q2 | 1.72 Billion JPY | 1028.11% |
| 2017 Q1 | -185.99 Million JPY | -361.08% |
| 2016 FY | 1.89 Billion JPY | 19.57% |
| 2016 Q3 | 279.26 Million JPY | -53.78% |
| 2016 Q4 | 71.24 Million JPY | -74.49% |
| 2016 Q2 | 604.23 Million JPY | -17.26% |
| 2016 Q1 | 730.3 Million JPY | 249.08% |
| 2015 Q3 | 37.55 Million JPY | -96.24% |
| 2015 FY | 1.58 Billion JPY | 57.47% |
| 2015 Q2 | 998.74 Million JPY | 2460.1% |
| 2015 Q1 | -42.31 Million JPY | -161.27% |
| 2015 Q4 | 209.2 Million JPY | 457.14% |
| 2014 Q1 | -22.09 Million JPY | -118.32% |
| 2014 Q4 | 69.06 Million JPY | 423.81% |
| 2014 Q3 | -21.32 Million JPY | -152.2% |
| 2014 Q2 | 40.86 Million JPY | 284.95% |
| 2014 FY | 1 Billion JPY | 576.15% |
| 2013 FY | 148.51 Million JPY | 8.26% |
| 2013 Q2 | 3.57 Million JPY | 0.0% |
| 2013 Q3 | 9.17 Million JPY | 156.73% |
| 2013 Q4 | 120.57 Million JPY | 1214.41% |
| 2012 FY | 137.18 Million JPY | 1275.79% |
| 2011 FY | 9.97 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | -690.581% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 676.153% |
| GNI Group Ltd. | 8.09 Billion JPY | 62.494% |
| Linical Co., Ltd. | 338.26 Million JPY | -797.469% |
| Trans Genic Inc. | 4.08 Million JPY | -74216.573% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 311.122% |
| Soiken Holdings Inc. | -662.2 Million JPY | 558.444% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -2097.41% |
| AnGes, Inc. | -7.43 Billion JPY | 140.817% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 335.676% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 142.205% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -1526.1% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 489.208% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 363.323% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 351.103% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 473.682% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 1037.964% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 348.835% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 313.479% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 256.607% |
| Ribomic Inc. | -1.02 Billion JPY | 396.399% |
| SanBio Company Limited | -2.64 Billion JPY | 214.82% |
| Healios K.K. | -3.82 Billion JPY | 179.41% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 359.899% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 303.802% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 312.386% |
| StemRIM | -2.02 Billion JPY | 250.14% |
| CellSource Co., Ltd. | 923.14 Million JPY | -228.859% |
| FunPep Company Limited | -933.41 Million JPY | 425.239% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 455.421% |
| Stella Pharma Corporation | -763.74 Million JPY | 497.491% |
| TMS Co., Ltd. | -960.04 Million JPY | 416.219% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 368.654% |
| Cuorips Inc. | -632.18 Million JPY | 580.214% |
| K Pharma,Inc. | 260.33 Million JPY | -1066.148% |
| Takara Bio Inc. | 1.48 Billion JPY | -105.124% |
| ReproCELL Incorporated | -31.41 Million JPY | 9763.638% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -11408.954% |
| StemCell Institute Inc. | 310.98 Million JPY | -876.211% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -2020.453% |
| CellSeed Inc. | -846.53 Million JPY | 458.619% |